HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Time to abandon the term angiomyolipoma for non-PEComatous angiomyomatous (or angiomatous) oral tumors with adipocytes.

Abstract
Angiomyolipoma (AML) is the most common benign mesenchymal neoplasm of the kidneys with well-established clinical and morphological features. The oral and maxillofacial pathology literature contains several examples that identify angiomyomatous proliferations of the oral mucosa that contain an adipocytic component as analogous to classic renal AMLs although they differ significantly in their immunohistochemical phenotype. Herein, through review of the pertinent oral pathology literature and the detailed description of 2 lesions, one an oral angiomyoma with an adipocytic component and the other an apparently hamartomatous angioleiomyomatous proliferation with adipocytes, we provide, in our opinion, a solid argument against the use of the term AML for non-PEComatous oral tumors.
AuthorsKonstantinos I Tosios, Ioannis G Koutlas, Vasileios F Kyriakopoulos, Maria Balta, Nandia Theologie-Lygidakis, Emmanuel Vardas, Ioannis Iatrou
JournalOral surgery, oral medicine, oral pathology, oral radiology, and endodontics (Oral Surg Oral Med Oral Pathol Oral Radiol Endod) Vol. 110 Issue 4 Pg. 492-7 (Oct 2010) ISSN: 1528-395X [Electronic] United States
PMID20674420 (Publication Type: Case Reports, Journal Article, Review)
CopyrightCopyright © 2010 Mosby, Inc. All rights reserved.
Chemical References
  • Actins
  • Desmin
  • S100 Proteins
  • von Willebrand Factor
Topics
  • Actins (analysis)
  • Adipocytes (pathology)
  • Aged
  • Angiomyolipoma (classification, pathology)
  • Desmin (analysis)
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Male
  • Mouth Neoplasms (classification, pathology)
  • S100 Proteins (analysis)
  • Terminology as Topic
  • Young Adult
  • von Willebrand Factor (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: